PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.52%
Growth of 4.52% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
4.63%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.42%. Jim Chanos would check for structural cost disadvantages.
4.09%
Growth of 4.09% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-0.41%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.93%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
5.27%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 1.04%. Jim Chanos would check for waste.
4.73%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 1.22%. Jim Chanos would check for waste.
155.56%
Interest expense change of 155.56% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
6.48%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 0.70%. Jim Chanos would check for overinvestment.
-10.56%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-14.43%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-1.75%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-6.00%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-98.31%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-10.91%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-14.76%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-76.99%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
23.00%
Income change of 23.00% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
17.68%
Margin change of 17.68% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
22.99%
EPS change of 22.99% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
22.99%
Diluted EPS change of 22.99% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
0.00%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.07%. Joel Greenblatt would investigate strategy.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.06%. Joel Greenblatt would investigate strategy.